The effects of OPRM1 118A>G on methadone response in pain management in advanced cancer at end of life.

ABSTRACT: Cancer pain is the most feared symptom at end of life. Methadone has advantages over other opioids but is associated with significant variability in clinical response, making dosing challenging in practice. OPRM1 is the most studied pharmacogene associated with the pharmacodynamics of opioids, however reports on the association of the A118G polymorphism on opioid dose requirements are conflicting, with no reports including methadone as the primary intervention. This association study on OPRM1 A118G and response to methadone for pain management, includes a review of this genetic factor's role in inter-patient variability. Fifty-four adult patients with advanced cancer were recruited in a prospective, multi-centre, open label dose individualization study. Patient characteristics were not sho

SUBMITTER: Haupt LM 

PROVIDER: S-EPMC10858860 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature